v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
$ in Thousands
Total
At The Market Offering
Registered Direct Offering
Common stock – Class A
Preferred Stock
Preferred stock – Series A
Common stock
Common stock – Class A
Common stock
Common stock – Class A
At The Market Offering
Common stock
Common stock – Class A
Registered Direct Offering
Additional paid-in capital
Additional paid-in capital
At The Market Offering
Additional paid-in capital
Registered Direct Offering
Accumulated deficit
Beginning balance (in shares) at Dec. 31, 2024         0              
Beginning balance at Dec. 31, 2024 $ (7,810)       $ 0 $ 0     $ 400,183     $ (407,993)
Beginning balance (in shares) at Dec. 31, 2024           155,781            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon release of RSUs (in shares)           110            
Share repurchase related to Section 16 Officer tax coverage exchange (in shares)           (24)            
Share repurchase related to Section 16 Officer tax coverage exchange (1)               (1)      
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs (in shares)           16,807            
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs 4,401               4,401      
Issuance of common stock upon exercise of pre-funded warrants (in shares)           65,932            
Issuance of common stock in connection with warrant inducement, net of issuance costs (in shares)           18,544            
Issuance of common stock in connection with warrant inducement, net of issuance costs 1,889               1,889      
Issuance of common stock for convertible note principal and interest (in shares)           10,645            
Issuance of common stock for convertible note principal and interest 664               664      
Stock-based compensation - stock options, RSAs, RSUs 1,057               1,057      
Net loss (6,172)                     (6,172)
Ending balance (in shares) at Mar. 31, 2025         0              
Ending balance at Mar. 31, 2025 (5,972)       $ 0 $ 0     408,193     (414,165)
Ending balance (in shares) at Mar. 31, 2025           267,795            
Beginning balance (in shares) at Dec. 31, 2024         0              
Beginning balance at Dec. 31, 2024 (7,810)       $ 0 $ 0     400,183     (407,993)
Beginning balance (in shares) at Dec. 31, 2024           155,781            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss (12,622)                      
Ending balance (in shares) at Jun. 30, 2025         0              
Ending balance at Jun. 30, 2025 (9,971)       $ 0 $ 0     410,644     (420,615)
Ending balance (in shares) at Jun. 30, 2025           326,311            
Beginning balance (in shares) at Mar. 31, 2025         0              
Beginning balance at Mar. 31, 2025 (5,972)       $ 0 $ 0     408,193     (414,165)
Beginning balance (in shares) at Mar. 31, 2025           267,795            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon release of RSUs (in shares)           9            
Share repurchase related to Section 16 Officer tax coverage exchange (in shares)           (1)            
Issuance of pre-funded warrants and warrants in private placement, net of issuance costs (25)               (25)      
Issuance of common stock in settlement of accounts payable (in shares)           10,720            
Issuance of common stock in settlement of accounts payable 338               338      
Issuance of common stock in connection with warrant inducement, net of issuance costs (in shares)           41,481            
Issuance of common stock for convertible note principal and interest (in shares)           6,307            
Issuance of common stock for convertible note principal and interest 199               199      
Deferred financing costs for warrant modification 400               400      
Issuance of warrants with convertible debt 572               572      
Stock-based compensation - stock options, RSAs, RSUs 967               967      
Net loss (6,450)                     (6,450)
Ending balance (in shares) at Jun. 30, 2025         0              
Ending balance at Jun. 30, 2025 $ (9,971)       $ 0 $ 0     410,644     (420,615)
Ending balance (in shares) at Jun. 30, 2025           326,311            
Beginning balance (in shares) at Dec. 31, 2025 547,408       547,408              
Beginning balance at Dec. 31, 2025 $ 17,140       $ 0 $ 0     455,718     (438,578)
Beginning balance (in shares) at Dec. 31, 2025       2,165,559   2,165,559            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon release of RSUs (in shares)           73            
Share repurchase related to Section 16 Officer tax coverage exchange (in shares)           (4)            
Issuance of common stock upon conversion of preferred stock (in shares)         547,408 306,672            
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs (in shares)             2,203,615          
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs   $ 12,929               $ 12,929    
Issuance of pre-funded warrants and warrants in private placement, net of issuance costs 4,580               4,580      
Issuance of common stock upon exercise of pre-funded warrants (in shares)           945,136            
Issuance of common stock in settlement of accounts payable (in shares)           5,723            
Issuance of common stock in settlement of accounts payable 95               95      
Issuance of common stock upon exercise of warrant liability (in shares)           4,202            
Issuance of common stock for convertible note principal and interest (in shares)           159,030            
Issuance of common stock for convertible note principal and interest 973               973      
Issuance of common stock in relation to the convertible debt settlement (in shares)           50,000            
Issuance of common stock in relation to the convertible debt settlement 606               606      
Stock-based compensation - stock options, RSAs, RSUs 322               322      
Net loss (9,480)                     (9,480)
Ending balance (in shares) at Mar. 31, 2026         0              
Ending balance at Mar. 31, 2026 $ 27,165       $ 0 $ 0     475,223     (448,058)
Ending balance (in shares) at Mar. 31, 2026           5,840,006            
Beginning balance (in shares) at Dec. 31, 2025 547,408       547,408              
Beginning balance at Dec. 31, 2025 $ 17,140       $ 0 $ 0     455,718     (438,578)
Beginning balance (in shares) at Dec. 31, 2025       2,165,559   2,165,559            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Net loss $ (17,749)                      
Ending balance (in shares) at Jun. 30, 2026 0       0              
Ending balance at Jun. 30, 2026 $ 114,260       $ 0 $ 0     570,587     (456,327)
Ending balance (in shares) at Jun. 30, 2026       20,342,968   20,342,968            
Beginning balance (in shares) at Mar. 31, 2026         0              
Beginning balance at Mar. 31, 2026 27,165       $ 0 $ 0     475,223     (448,058)
Beginning balance (in shares) at Mar. 31, 2026           5,840,006            
Increase (Decrease) in Stockholders' Equity [Roll Forward]                        
Issuance of common stock upon release of RSUs (in shares)           12,615            
Share repurchase related to Section 16 Officer tax coverage exchange (in shares)           (3,648)            
Share repurchase related to Section 16 Officer tax coverage exchange (18)               (18)      
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs (in shares)             5,806,465 1,851,852        
Issuance of common stock under At-The-Market Offering, net of issuance costs and related warrants in registered offering, net of issuance costs   $ 32,574 $ 23,130             $ 32,574 $ 23,130  
Issuance of common stock, pre-funded warrants and warrants in private placement, net of issuance costs (in shares)           2,623,420            
Issuance of common stock, pre-funded warrants and warrants in private placement, net of issuance costs 27,722               27,722      
Issuance of common stock upon exercise of pre-funded warrants (in shares)           1,651,914            
Issuance of common stock upon exercise of warrants (in shares)           1,807,941            
Issuance of common stock upon exercise of warrants 9,638               9,638      
Issuance of common stock upon exercise of warrant liability (in shares)           16,440            
Issuance of common stock upon exercise of warrant liability 123               123      
Issuance of common stock for convertible note principal and interest (in shares)           735,963            
Issuance of common stock for convertible note principal and interest 2,006               2,006      
Stock-based compensation - stock options, RSAs, RSUs 189               189      
Net loss $ (8,269)                     (8,269)
Ending balance (in shares) at Jun. 30, 2026 0       0              
Ending balance at Jun. 30, 2026 $ 114,260       $ 0 $ 0     $ 570,587     $ (456,327)
Ending balance (in shares) at Jun. 30, 2026       20,342,968   20,342,968